[The role of endothelin in acute renal failure]. 1995

A Peco-Antitsh, and D Nastitsh-Miritsh, and M Popovitsh-Rolovitsh, and G Adanja, and M Kostitsh, and N Jovanovitsh, and V Paripovitsh
University Children's Hospital, Belgrade.

During the study of the pathological significance of circulating endothelin (ET) in acute renal failure (ARF) we measured ET in 7 children (mean age 8.8+4.4 years) with ARF in the most severe phase, and 3.7+3.5 months later in the recovery period. Twenty-seven healthy children (mean age 11.1+/- 6.3 years) were included in the study as controls. Plasma ET level was measured by highly sensitive and specific radioimmunoassay for ET-1 and ET-2 (ET 1/2, Biomedica, Vienna). Plasma ET was significantly higher in the most severe phase of ARF than in the recovery period, but comparing to plasma ET in the healthy children, the difference was only on borderline statistical significance. Since plasma concentrations of creatinine did not correlate with plasma ET in patients, either in acute or in the recovery phase of disease, we concluded that decreased glomerular filtration (GFR) was not the main factor determining the increased ET in ARF. We suggest that elevated plasma ET in ARF may be secondary to vascular endothelial dysfunction and speculate that engancement synthesis of endothelial relaxing factor (EDRF) inhibits ET synthesis during the recovery period. The pathogenetic role of circulating ET in ARF cannot be determined from the present study.

UI MeSH Term Description Entries
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D005260 Female Females
D005919 Glomerular Filtration Rate The volume of water filtered out of plasma through glomerular capillary walls into Bowman's capsules per unit of time. It is considered to be equivalent to INULIN clearance. Filtration Rate, Glomerular,Filtration Rates, Glomerular,Glomerular Filtration Rates,Rate, Glomerular Filtration,Rates, Glomerular Filtration
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016232 Endothelins 21-Amino-acid peptides produced by vascular endothelial cells and functioning as potent vasoconstrictors. The endothelin family consists of three members, ENDOTHELIN-1; ENDOTHELIN-2; and ENDOTHELIN-3. All three peptides contain 21 amino acids, but vary in amino acid composition. The three peptides produce vasoconstrictor and pressor responses in various parts of the body. However, the quantitative profiles of the pharmacological activities are considerably different among the three isopeptides. Endothelium-Derived Vasoconstrictor Factors,Endothelin,Vasoconstrictor Factors, Endothelium-Derived
D058186 Acute Kidney Injury Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions. Acute Kidney Failure,Acute Kidney Insufficiency,Acute Renal Failure,Acute Renal Injury,Acute Renal Insufficiency,Kidney Failure, Acute,Kidney Insufficiency, Acute,Renal Failure, Acute,Renal Insufficiency, Acute,Acute Kidney Failures,Acute Kidney Injuries,Acute Kidney Insufficiencies,Acute Renal Failures,Acute Renal Injuries,Acute Renal Insufficiencies,Kidney Failures, Acute,Kidney Injuries, Acute,Kidney Injury, Acute,Kidney Insufficiencies, Acute,Renal Failures, Acute,Renal Injuries, Acute,Renal Injury, Acute,Renal Insufficiencies, Acute

Related Publications

A Peco-Antitsh, and D Nastitsh-Miritsh, and M Popovitsh-Rolovitsh, and G Adanja, and M Kostitsh, and N Jovanovitsh, and V Paripovitsh
January 1997, Blood purification,
A Peco-Antitsh, and D Nastitsh-Miritsh, and M Popovitsh-Rolovitsh, and G Adanja, and M Kostitsh, and N Jovanovitsh, and V Paripovitsh
January 1990, Life sciences,
A Peco-Antitsh, and D Nastitsh-Miritsh, and M Popovitsh-Rolovitsh, and G Adanja, and M Kostitsh, and N Jovanovitsh, and V Paripovitsh
April 2000, Drug news & perspectives,
A Peco-Antitsh, and D Nastitsh-Miritsh, and M Popovitsh-Rolovitsh, and G Adanja, and M Kostitsh, and N Jovanovitsh, and V Paripovitsh
July 1997, Current opinion in nephrology and hypertension,
A Peco-Antitsh, and D Nastitsh-Miritsh, and M Popovitsh-Rolovitsh, and G Adanja, and M Kostitsh, and N Jovanovitsh, and V Paripovitsh
July 1996, Renal failure,
A Peco-Antitsh, and D Nastitsh-Miritsh, and M Popovitsh-Rolovitsh, and G Adanja, and M Kostitsh, and N Jovanovitsh, and V Paripovitsh
October 2002, Journal of cardiovascular pharmacology,
A Peco-Antitsh, and D Nastitsh-Miritsh, and M Popovitsh-Rolovitsh, and G Adanja, and M Kostitsh, and N Jovanovitsh, and V Paripovitsh
July 1995, The Journal of pharmacology and experimental therapeutics,
A Peco-Antitsh, and D Nastitsh-Miritsh, and M Popovitsh-Rolovitsh, and G Adanja, and M Kostitsh, and N Jovanovitsh, and V Paripovitsh
May 1999, Journal of the American Society of Nephrology : JASN,
A Peco-Antitsh, and D Nastitsh-Miritsh, and M Popovitsh-Rolovitsh, and G Adanja, and M Kostitsh, and N Jovanovitsh, and V Paripovitsh
January 2006, Critical care nursing quarterly,
A Peco-Antitsh, and D Nastitsh-Miritsh, and M Popovitsh-Rolovitsh, and G Adanja, and M Kostitsh, and N Jovanovitsh, and V Paripovitsh
November 1988, Lancet (London, England),
Copied contents to your clipboard!